Clinical Trials Logo
  1. Home
  2. Inflammatory Bowel Disease
  3. NCT06405503
  4. Details
NCT06405503 Clinical Trial

Impact of Primary Language on Treatment and Outcomes in Inflammatory Bowel Disease

Inflammatory Bowel Disease Clinical Trial

Official title:
Impact of Primary Language on Treatment and Outcomes in Inflammatory Bowel Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06405503
Other study ID # STUDY00004331
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 1, 2024
Est. completion date June 30, 2025

Study information
Verified date May 2024
Source University of Texas at Austin
Contact Linda A Feagins, MD
Phone 512-324-7831
Email linda.feagins@austin.utexas.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A thorough discussion of treatment options to manage inflammatory bowel disease (IBD), including the risks and benefits of each class of medication, can be a complex discussion and time consuming. Having to use a translator adds an additional layer of time and complexity to these discussions as well as potential misunderstanding. Further, in addition to language, cultural differences can also play into treatment acceptance. This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 206
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years of age - Confirmed diagnosis of IBD (CD, UC or indeterminate colitis) - Willing to provide consent for participation - Managed at an outpatient clinic either the Yale New Haven Hospital system or the University of Texas at Austin Hospital system. Exclusion Criteria: - Patients <18 - No confirmed diagnosis of IBD - Not planning to continue care at either study site (i.e. presenting for a consultation only) - Unwilling to provide signed consent

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• NO INTERVENTION
NO INTERVENTION - OBSERVATIONAL ONLY

Locations
Country Name City State
United States Dell Medical School at the University of Texas at Austin Austin Texas

Sponsors (3)
Lead Sponsor Collaborator
University of Texas at Austin Bristol-Myers Squibb, Yale University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Current use of advanced therapy Use of or prescription of a biologic or small molecule therapy to treat inflammatory bowel disease baseline
Secondary IBD-related disease complications 6 months
Secondary IBD-related disease complications 12 months
See also
  Status Clinical Trial Phase
Withdrawn NCT03278912 - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT05579392 - A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis N/A
Completed NCT03264690 - Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
Recruiting NCT02861053 - Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ? N/A
Recruiting NCT02275676 - Resting Energy Expenditure and Nutritional Status in IBD N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02161640 - Vascular Dysfunction in Paediatric IBD N/A
Completed NCT01860651 - Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease N/A
Completed NCT01933867 - Water-aided Colonoscopy in Inflammatory Bowel Disease Patients N/A
Completed NCT01852760 - Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound N/A
Completed NCT01666535 - Infliximab IBD Influenza Vaccine Study N/A
Completed NCT01688557 - Trial on Innovative Technologies in Colonoscopy N/A
Completed NCT01676324 - FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD) N/A
Completed NCT01692743 - Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Phase 3
Completed NCT01981616 - Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab Phase 1
Completed NCT01557387 - Real-time Diagnosis of Pseudopolyps During Colonoscopy
Completed NCT01221818 - A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects Phase 1
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A